4.8 Article

Repression of E-cadherin by the polycomb group protein EZH2 in cancer

Journal

ONCOGENE
Volume 27, Issue 58, Pages 7274-7284

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2008.333

Keywords

polycomb group protein; histone; EZH2; E-cadherin; epigenetics

Funding

  1. National Institutes of Health [R01 CA97063, U01 CA111275, P50 CA69568]
  2. Department of Defense [PC040517, PC051081, PC060266, R01CA107469]

Ask authors/readers for more resources

Enhancer of zeste homolog 2 (EZH2) is a critical component of the polycomb-repressive complex 2 (PRC2), which is involved in gene silencing and histone H3 lysine 27 methylation. EZH2 has a master regulatory function in controlling such processes as stem cell differentiation, cell proliferation, early embryogenesis and X chromosome inactivation. Although benign epithelial cells express very low levels of EZH2, increased levels of EZH2 have been observed in aggressive solid tumors such as those of the prostate, breast and bladder. The mechanism by which EZH2 mediates tumor aggressiveness is unclear. Here, we demonstrate that EZH2 mediates transcriptional silencing of the tumor suppressor gene E-cadherin by trimethylation of H3 lysine 27. Histone deacetylase inhibitors can prevent EZH2-mediated repression of E-cadherin and attenuate cell invasion, suggesting a possible mechanism that may be useful for the development of therapeutic treatments. Taken together, these observations provide a novel mechanism of E-cadherin regulation and establish a functional link between dysregulation of EZH2 and repression of E-cadherin during cancer progression.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available